Literature DB >> 8601361

Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques.

J Hida1, M Yasutomi, K Shindoh, M Kitaoka, K Fujimoto, S Ieda, N Machidera, R Kubo, E Morikawa, H Inufusa, M Watatani, K Okuno.   

Abstract

PURPOSE: The usefulness of postoperative carcinoembryonic antigen (CEA) monitoring and improvements in imaging techniques have renewed enthusiasm for second-look operations (SLO) as the most effective treatment for recurrent colorectal cancer by reresection following early detection. The aim of our study is to evaluate the role of CEA and imaging techniques-directed SLO.
METHODS: Seven hundred fifty-six patients with Dukes Stages B and C, who had undergone curative resection, were monitored postoperatively using CEA and imaging techniques. An SLO was performed on any potentially resectable recurrence, and in addition, an SLO was done when a persistently rising CEA value was detected.
RESULTS: Recurrence developed in 18.8 percent (142/756) of patients, and 90.8 percent (129/142) of the recurrences were detected within the first three years following curative resection. When comparing carcinomas of the colon with that of the rectum, the former were associated with significantly more hepatic and intraabdominal recurrences, whereas the latter had significantly more locoregional and pulmonary recurrences. Seventy-two patients underwent SLO. Of these patients, 54.2 percent (39/72) had all of their disease resected, and 1.4 percent (1/72) had no detectable disease at the SLO. Among the 142 patients with recurrence, 71 (50 percent) patients underwent SLO. The resectable group at SLO carried a significantly better survival than the unresectable recurrence group (41.3 vs. 5.2 percent; P<0.01).
CONCLUSIONS: Complete removal of colorectal cancer recurrences by SLO, on the basis of postoperative, follow-up CEA and imaging technique findings, results in improved survival.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8601361     DOI: 10.1007/bf02048273

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

Review 1.  Management of rectal cancer.

Authors:  James S Wu; Victor W Fazio
Journal:  J Gastrointest Surg       Date:  2004-02       Impact factor: 3.452

2.  Isolated diaphragmatic metastasis originated from adenocarcinoma of the colon.

Authors:  Kang Hong Lee; Chang Sik Yu; Hwan Namgung; Hee Cheol Kim; Jin Cheon Kim
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

3.  Long-term functional outcome of colonic J-pouch reconstruction after low anterior resection for rectal cancer.

Authors:  Jin-Ichi Hida; Takehito Yoshifuji; Kiyotaka Okuno; Tomohiko Matsuzaki; Toshihiro Uchida; Eizaburou Ishimaru; Tadao Tokoro; Masayuki Yasutomi; Hitoshi Shiozaki
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 4.  High ligation of the inferior mesenteric artery in rectal cancer surgery.

Authors:  Jin-Ichi Hida; Kiyotaka Okuno
Journal:  Surg Today       Date:  2012-10-07       Impact factor: 2.549

5.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.

Authors:  F L Flanagan; F Dehdashti; O A Ogunbiyi; I J Kodner; B A Siegel
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

Review 6.  Distal dissection in total mesorectal excision, and preoperative chemoradiotherapy and lateral lymph node dissection for rectal cancer.

Authors:  Jin-ichi Hida; Kiyotaka Okuno; Tadao Tokoro
Journal:  Surg Today       Date:  2013-12-22       Impact factor: 2.549

7.  The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.

Authors:  Hyun Hoon Chung; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

Review 8.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.